BackgroundThe tumor immune microenvironment (TIME) has been recognized to be an imperative factor facilitating the acquisition of many cancer-related hallmarks and is a critical target for targeted bi
Epigenetic immunomodulation by association of guadecitabine with ipilimumab (NIBIT-M4 Phase Ib trial, NCT02608437) has been shown to be safe and tolerable in advanced melanoma and to have significant
Herein, we set out to investigate the responses to first-line therapies (DOS, XELOX, and anti-HER2-based therapies) for GC through a comprehensive proteomic analysis. We constructed a GC cohort that c
